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Background
Early Larynx Cancer (ELC) has been historically treated
with radiotherapy and the outcomes reported vary consid-
erably. We analyze the patient and treatment related
parameters that may influence the frequency of local con-
trol, overall and disease free survival; and voice preserva-
tion.
Patients and methods
Thirty patients were treated with radiation therapy
between 1996–2002. We use the AJCC 2002 classification
for the patients and also they were stratified according to
the extent of disease. Variables like age, clinical stage,
tumor extension, involvement of anterior commissure,
Karnofsky index, total dose, field size, protraction, beam
energy and others were used for the statistical analysis.
Results
We found 30 male patients with a median age of 64 years
(range 35 – 88). Twelve patients were T1a, 10 patients T1b
and 8 patients had T2 tumor; according to the tumor
extension, 11(37%) had affected one vocal cord, 13(43%)
one vocal cord and anterior commissure and 6 (20%) had
affected two cords and the anterior commissure. The
median follow up was 53.2 months and a range between
5 and 114 months. All patients were treated with a contin-
uous course of radiotherapy with a fraction size of 2 Gy
per day, the median dose was 68.7 Gy (56 – 81 Gy), the
median of protraction was 53 days (range 42 – 77). Co60
was used  in 25 patients and 6 MV in 5 patients, the field
size was equal to or smaller than 7 × 7 cm2 with a larynx
box technique for all. In 27 patients the dose calculation
was made with a Cadplan® system to an isodose curve of
95% to the tumor. Local control rates at five years were as
follows: T1a 100%, T1b 75% and T2 37.5%. The overall
survival to 5 years for the entire group was 73.3%. Voice
preservation was reached in 25 patients (83%) until the
last visit. The reported toxicity was mucositis in 27
patients (90%), 3 of them required a nasogastric tube, no
surgical treatment was required. Radiotherapy was not the
cause of death in any patient. There were 8 recurrences, 3
of them were rescued with total laryngectomy, one patient
was treated with partial laryngectomy and presented a
new recurrence, 4 patients did not accept any further ther-
apy. Only those variables like stage (p  0.008), tumor
extension (p 0.009) Karnofsky index 90 Vs 100 (p 0.008),
and anterior commissure involvement (p 0.04) had a sig-
nificant association with local control in univariate analy-
sis.
Conclusion
Radiation therapy cures a high percentage of patients with
T1 glottic carcinoma and has a low rate of severe compli-
cations. For T2 glottic carcinoma an adequate selection
and staging for the election of the best treatment option is
necessary, The major tumor-related parameter that influ-
ences the likelihood of local control is T stage and exten-
sion of disease.
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